@article{e10f8c31ea534404b246026a820c92c0,
title = "From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit",
abstract = "The second Kidney Cancer Research Summit was held virtually in October 2020. The meeting gathered worldwide experts in the field of kidney cancer, including basic, translational, and clinical scientists as well as patient advocates. Novel studies were presented, addressing areas of unmet need related to different topics. These include novel metabolic targets, promising immunotherapeutic regimens, predictive genomic and transcriptomic biomarkers, and variant histologies of renal cell carcinoma (RCC). With the development of pioneering technologies, and an unprecedented commitment to kidney cancer research, the field has tremendously evolved. This perspective aims to summarize the different sessions of the conference, outline major advances in the understanding of RCC and discuss current challenges faced by the field.",
author = "Choueiri, {Toni K.} and Laurence Albiges and Atkins, {Michael B.} and Ziad Bakouny and Gennady Bratslavsky and Braun, {David A.} and Haas, {Naomi B.} and Haanen, {John B.A.G.} and Hakimi, {A. Ari} and Jewett, {Michael A.S.} and Eric Jonasch and Kaelin, {William G.} and Payal Kapur and Chris Labaki and Bryan Lewis and McDermott, {David F.} and Pal, {Sumanta K.} and Kevin Pels and Susan Poteat and Thomas Powles and Rathmell, {W. Kimryn} and Rini, {Brian I.} and Sabina Signoretti and Tannir, {Nizar M.} and Uzzo, {Robert G.} and Hammers, {Hans J.}",
note = "Funding Information: T.K. Choueiri reports grants, personal fees, non-financial support, and other support from Merck, BMS, Exelixis, EMD Serono, and Pfizer, as well as other support from KidneyCAN during the conduct of the study; T.K. Choueiri also reports other support from NCCN panel, GUSC of the NCI, as well as personal fees from Up-to-Date outside the submitted work. L. Albiges reports other support from BMS, Novartis, Pfizer, IPSEN, Astellas, MSD, Merck & Co, Janssen, AstraZeneca, and Eisai outside the submitted work. M.B. Atkins reports grants and personal fees from BMS, as well as personal fees from Merck, Genentech-Roche, Novartis, Eisai, Pfizer, Exelixis, Werewolf, Pyxis Oncololgy, Asher Bio, Simcha, Takeda, SeaGen, AstraZeneca, Calithera, SAB Bio, X4 Pharma, Aveo, Iovance, Allogene, and Neoleukin outside the submitted work; M.B. Atkins also reports stock ownership in Pyxis Oncology and Werewolf. Z. Bakouny reports non-financial support from Bristol Myers Squibb, grants from Genentech/ imCORE, and personal fees from UpToDate outside the submitted work. G. Bratslavsky reports other support from Merck and J&J outside the submitted work. D.A. Braun reports grants and personal fees from Exelixis; personal fees from AVEO, MDedge, CancerNetwork, CancerExpert Now, LM Education and Exchange Services, Trinity Group, and Insight Strategy; and non-financial support from Bristol Myers Squibb outside the submitted work. J.B.A.G. Haanen reports other support from Achilles Tx, Iovance BioTx, Instil Bio, Ipsen, Molecular Partners, Merck Serono, PokeAcel, Pfizer, Roche, Sanofi, and T-Knife; grants from Asher Bio, Amgen, and BMS; grants and other support from BioNTech, MSD, and Novartis; and grants and personal fees from Neogene Tx outside the submitted work. A.A. Hakimi reports personal fees from Merck outside the submitted work. M.A.S. Jewett reports Board Member and Chair, MAB of the International Kidney Cancer Coalition (advocacy volunteer group). E. Jonasch reports personal fees from Aveo, Calithera, Eisai, Exelixis, Ipsen, and Pfizer; grants and personal fees from Aravive, Merck, NiKang, and Novartis; and grants from Arrowhead during the conduct of the study. C. Labaki reports grants from Roche/Genentech outside the submitted work. D.F. McDermott reports personal fees from BMS, Merck, and Pfizer outside the submitted work. S.K. Pal reports personal fees from F. Hoffman- Publisher Copyright: {\textcopyright} 2021 American Association for Cancer Research.",
year = "2022",
month = mar,
day = "1",
doi = "10.1158/1078-0432.CCR-21-3238",
language = "English (US)",
volume = "28",
pages = "831--839",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "5",
}